Hypoxia signaling in human diseases and therapeutic targets
Autor: | Jae W. Lee, Cynthia Ju, Holger K. Eltzschig, Junsuk Ko |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Lung Diseases Heart Diseases Clinical Biochemistry lcsh:Medicine Single gene Review Article Biochemistry lcsh:Biochemistry 03 medical and health sciences 0302 clinical medicine Downregulation and upregulation Correspondence medicine Animals Humans Biological therapy lcsh:QD415-436 Hypoxia Exercise Molecular Biology Organ system Kidney business.industry Liver Diseases lcsh:R Energy metabolism Hypoxia (medical) 3. Good health 030104 developmental biology Chronic disease medicine.anatomical_structure Erythropoietin 030220 oncology & carcinogenesis Cancer research Molecular Medicine Kidney Diseases Hypoxia-Inducible Factor 1 medicine.symptom Signal transduction business medicine.drug Signal Transduction |
Zdroj: | Experimental and Molecular Medicine, Vol 51, Iss 6, Pp 1-13 (2019) Experimental & Molecular Medicine |
ISSN: | 2092-6413 1226-3613 |
Popis: | Since the discovery of hypoxia-inducible factor (HIF), numerous studies on the hypoxia signaling pathway have been performed. The role of HIF stabilization during hypoxia has been extended from the induction of a single gene erythropoietin to the upregulation of a couple of hundred downstream targets, which demonstrates the complexity and importance of the HIF signaling pathway. Accordingly, HIF and its downstream targets are emerging as novel therapeutic options to treat various organ injuries. In this review, we discuss the current understanding of HIF signaling in four different organ systems, including the heart, lung, liver, and kidney. We also discuss the divergent roles of HIF in acute and chronic disease conditions and their revealed functions. Finally, we introduce some of the efforts that are being performed to translate our current knowledge in hypoxia signaling to clinical medicine. Low oxygen: Protein signalling in human disease A protein family that plays diverse roles in acute and chronic hypoxia (low oxygen) may prove valuable in developing novel therapies for different diseases. Hypoxia, the short- or long-term depletion of oxygen in cells, tissues and organs, is involved in many disease conditions. Holger Eltzschig at the McGovern Medical School in Houston, USA, and co-workers reviewed research into the roles of a key hypoxia regulator, the hypoxia-inducible factor (HIF) protein group, in diseases affecting the heart, lung, liver and kidneys. HIF protein activity is often beneficial in acute conditions such as myocardial ischemia, sending signals to protect cells and increasing tissue tolerance to hypoxia. However, during chronic hypoxia, HIF signaling may contribute to the progression of disease, for example in pulmonary fibrosis. HIF stabilizers and HIF-induced targets as drugs could prove valuable in future treatments. |
Databáze: | OpenAIRE |
Externí odkaz: |